JP5734856B2 - 癌及び線維症疾患の治療に使用される医薬及び組成物ならびにその使用 - Google Patents

癌及び線維症疾患の治療に使用される医薬及び組成物ならびにその使用 Download PDF

Info

Publication number
JP5734856B2
JP5734856B2 JP2011530354A JP2011530354A JP5734856B2 JP 5734856 B2 JP5734856 B2 JP 5734856B2 JP 2011530354 A JP2011530354 A JP 2011530354A JP 2011530354 A JP2011530354 A JP 2011530354A JP 5734856 B2 JP5734856 B2 JP 5734856B2
Authority
JP
Japan
Prior art keywords
peptide
pharmaceutical composition
cancer
liver
pdgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011530354A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012504941A5 (enExample
JP2012504941A (ja
Inventor
ファン、ラン
ジョウ、ファ
ユアン、シェンタオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2012504941A publication Critical patent/JP2012504941A/ja
Publication of JP2012504941A5 publication Critical patent/JP2012504941A5/ja
Application granted granted Critical
Publication of JP5734856B2 publication Critical patent/JP5734856B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2011530354A 2008-10-09 2009-09-21 癌及び線維症疾患の治療に使用される医薬及び組成物ならびにその使用 Expired - Fee Related JP5734856B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200810200937.8 2008-10-09
CN2008102009378A CN101392026B (zh) 2008-10-09 2008-10-09 用于预防和治疗纤维化类疾病以及肝癌的多肽
PCT/CN2009/074048 WO2010040305A1 (en) 2008-10-09 2009-09-21 Pharmaceutical being used for treating cancer and fibrosis disease and the composition and uses thereof

Publications (3)

Publication Number Publication Date
JP2012504941A JP2012504941A (ja) 2012-03-01
JP2012504941A5 JP2012504941A5 (enExample) 2012-11-08
JP5734856B2 true JP5734856B2 (ja) 2015-06-17

Family

ID=40492557

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011530354A Expired - Fee Related JP5734856B2 (ja) 2008-10-09 2009-09-21 癌及び線維症疾患の治療に使用される医薬及び組成物ならびにその使用

Country Status (5)

Country Link
US (1) US8637467B2 (enExample)
EP (1) EP2344528B1 (enExample)
JP (1) JP5734856B2 (enExample)
CN (1) CN101392026B (enExample)
WO (1) WO2010040305A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101392026B (zh) 2008-10-09 2011-11-09 黄岚 用于预防和治疗纤维化类疾病以及肝癌的多肽
CN111701020A (zh) * 2020-06-08 2020-09-25 南通大学 一种治疗pdgf诱导的肝纤维化的分子靶点

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
CN1330664A (zh) 1998-09-30 2002-01-09 路德维格癌症研究所 血小板衍生生长因子c、其编码dna及其应用
US20030211994A1 (en) * 1998-09-30 2003-11-13 Ludwig Institute For Cancer Research Composition and method for modulating vasculogenesis or angiogenesis
DE69936733T2 (de) 1998-12-22 2008-06-05 Janssen Pharmaceutica N.V. Vaskulärer endothelialer wachstumsfaktor x
CN1355209A (zh) * 2000-11-24 2002-06-26 复旦大学 一种新的多肽——钙依赖性氯离子通道16.72和编码这种多肽的多核苷酸
WO2003102140A2 (en) * 2002-05-31 2003-12-11 Children's Hospital Medical Center Cftr modifier genes and expressed polypeptides useful in treating cystic fibrosis
AU2004209668A1 (en) * 2003-02-04 2004-08-19 Flanders Interuniversity Institute For Biotechnology VEGF-B and PDGF modulation of stem cells
WO2007022287A2 (en) 2005-08-15 2007-02-22 Vegenics Limited Modified vegf and pdgf with improved angiogenic properties
CN101392026B (zh) 2008-10-09 2011-11-09 黄岚 用于预防和治疗纤维化类疾病以及肝癌的多肽

Also Published As

Publication number Publication date
CN101392026A (zh) 2009-03-25
US20110263513A1 (en) 2011-10-27
EP2344528A4 (en) 2012-03-28
EP2344528A1 (en) 2011-07-20
CN101392026B (zh) 2011-11-09
JP2012504941A (ja) 2012-03-01
WO2010040305A1 (en) 2010-04-15
EP2344528B1 (en) 2013-12-18
US8637467B2 (en) 2014-01-28

Similar Documents

Publication Publication Date Title
ES2281704T3 (es) Procedimientos y compuestos para inhibir el crecimiento de celulas neoplasicas.
JP6420459B2 (ja) 線維症抑制活性を有するペプチド及びこれを含む組成物
EP1833504A2 (en) Sustained delivery of pdgf using self-assembling peptide nanofibers
WO2011119009A2 (en) Peptides for promoting angiogenesis and an use thereof
US20090036369A1 (en) Anti-tumor agents comprising r-spondins
Wu et al. Anti-tumor effects of a novel chimeric peptide on S180 and H22 xenografts bearing nude mice
BR112021008797A2 (pt) Polipeptídeos para o tratamento de síndromes de estresse, imunorreação e derrame
CN107629114B (zh) 多肽、其衍生物及其在制备抗肺纤维化的药物中的应用
JP5734856B2 (ja) 癌及び線維症疾患の治療に使用される医薬及び組成物ならびにその使用
ES2330918T3 (es) Inhibidor del activador del factor de crecimiento de hepatocitos para usar en la modulacion de la angiogenesis y la cardiovascularizacion.
WO2010141946A1 (en) Peptide-coated cell localization to diseased or damaged tissues and methods related thereto
EP3059243B1 (en) Yap protein inhibiting polypeptide and application thereof
US20030228283A1 (en) Preventing secondary lymphedema with VEGF-D DNA
JP4094814B2 (ja) 血管新生抑制剤
EP2552940A2 (en) Peptides for promoting angiogenesis and an use thereof
KR101123130B1 (ko) Ｐｔｋ７ 단백질의 기능 저해를 통한 세포의 이동, 침윤 또는 혈관신생 억제제
CN107446024B (zh) 一种可拮抗ddx3蛋白rna结合活性的多肽dip-13及其应用
JPWO1999055361A1 (ja) 血管新生抑制剤
CN116120401A (zh) 一种抗黑色素瘤活性多肽kw13、药物及应用
KR102216566B1 (ko) 종양 혈관형성을 억제하는 vegf 딥 블로커를 포함하는 암 치료용 조성물 및 이의 제조방법
CN119751562B (zh) 一种胰酶响应的生物活性肽及利用其制备的纳米纤维水凝胶和应用
KR20130060846A (ko) 암세포 특이적 세포괴사 유도 및 암 소멸 효과를 나타내는 세포사 유도 융합 펩타이드
CN109734779B (zh) 一种靶向Tie-1的多肽及其应用
CN102432671A (zh) 能够抑制肝癌生长转移的靶向多肽spscvlp及用途
Tesoro et al. TITTLE: Cardioprotective Effect of New NIL10 Nanoparticles Through IL10 Receptor/STAT3 Activation in Mice and Pigs Subjected Acute Myocardial Infarction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150114

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150317

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150415

R150 Certificate of patent or registration of utility model

Ref document number: 5734856

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees